An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination With Nintedanib (Ofev) in Patients With Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase IV
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Genentech; Roche
- 08 Jun 2017 Status changed from active, no longer recruiting to completed.
- 24 May 2017 Prespecified interim analysis results (n=41) presented at the 113th International Conference of the American Thoracic Society
- 08 Mar 2017 Planned End Date changed from 1 May 2017 to 31 May 2017.